Switch theme
Sign up to access all valuation multiples
Zentiva SA is a Romania-based producer of medicines on the local market. The product portfolio of Zentiva SA includes more than 126 products for human use, such as solids (tablets, capsules, and pellets), generic products, and injectable solutions. The company provides products for therapeutic areas such as Cardiovascular diseases, Anti-inflammatory and pain-relieving medications, urologists, Blood diseases, Gastrointestinal and metabolic disorders, Central nervous system, Medicines against infections, and Diseases of the respiratory system.
1962
1.1K+
Last FY Revenue $260M
Last FY EBITDA $74.8M
$734M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Zentiva achieved revenue of $260M and an EBITDA of $74.8M.
Zentiva expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zentiva valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $260M | XXX | XXX | XXX |
| Gross Profit | XXX | $153M | XXX | XXX | XXX |
| Gross Margin | XXX | 59% | XXX | XXX | XXX |
| EBITDA | XXX | $74.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 29% | XXX | XXX | XXX |
| EBIT | XXX | $63.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | 24% | XXX | XXX | XXX |
| Net Profit | XXX | $58.4M | XXX | XXX | XXX |
| Net Margin | XXX | 22% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Zentiva's stock price is RON 5 (or $1).
Zentiva has current market cap of RON 3.2B (or $735M), and EV of RON 3.1B (or $734M).
See Zentiva trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $734M | $735M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Zentiva has market cap of $735M and EV of $734M.
Zentiva's trades at 2.8x EV/Revenue multiple, and 9.8x EV/EBITDA.
Equity research analysts estimate Zentiva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zentiva's P/E ratio is not available.
See valuation multiples for Zentiva and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $735M | XXX | $735M | XXX | XXX | XXX |
| EV (current) | $734M | XXX | $734M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 11.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 12.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 85.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZentiva's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Zentiva's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zentiva's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zentiva and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zentiva acquired XXX companies to date.
Last acquisition by Zentiva was XXXXXXXX, XXXXX XXXXX XXXXXX . Zentiva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zentiva founded? | Zentiva was founded in 1962. |
| Where is Zentiva headquartered? | Zentiva is headquartered in Romania. |
| How many employees does Zentiva have? | As of today, Zentiva has 1.1K+ employees. |
| Is Zentiva publicy listed? | Yes, Zentiva is a public company listed on BSE. |
| What is the stock symbol of Zentiva? | Zentiva trades under SCD ticker. |
| When did Zentiva go public? | Zentiva went public in 1998. |
| Who are competitors of Zentiva? | Similar companies to Zentiva include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Zentiva? | Zentiva's current market cap is $735M |
| Is Zentiva profitable? | Yes, Zentiva is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
